ARCHIVES

Costs of Rosenberg Regimen Could Hinder cooperative Group Trials

This article is from The Cancer Letter archive.

Vol. 12 No. 01 | January 3, 1986

Download PDF Visit The Full Archive

Related Articles

Phase III Trial Would Give Clearer Picture Of C225 Role.

February 15, 2002

Senate Committee Schedules Hearing for FDA Acting Commissioner von Eschenbach.

July 28, 2006

New NCI Division Wins Approval To Fund Grants In Basic Biobehavioral Research

April 17, 1998

Rosenberg’s Latest Results: 22% Response Seen With LAK/IL-2, 13% With High Dose IL-2 Alone

April 10, 1987

FDA Approves Votrient For Renal Cell Carcinoma

October 23, 2009

Also In sudden policy change, NIH proposes one-year ban on consulting by employees.

October 1, 2004